In patients with drug-resistant epilepsy, retention rate was high after brivaracetam treatment initiation (85.8% after 3 months, 73.9% after 6 months, and 64.9% after 9 months).

Seizure frequency decreased from baseline in 32.0%, 37.1%, and 37.3% of patients after 3, 6, and 9 months’ treatment, respectively.

The percentage of patients with 3-month seizure freedom increased from 3.2% after 3 months’ treatment to 10.2% and 10.7% after 6 and 9 months’ treatment, respectively.

Qualitative seizure improvements were reported in 61/138, 45/116, and 35/81 of patients after 3, 6, and 9 months, respectively.